[ASAP] Monitoring Sorafenib Resistance and Efficacy in Hepatocellular Carcinoma Using [18F]Alfatide II and [18F]Fluorodeoxyglucose Positron Emission Tomography 🔗 Access full article via ACS Molecular Pharmaceutics Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.4c01218 Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
